Catalyst Wire Dossier Catalyst Wire Dossier

fosaprepitant (MK-0517) + ondansetron

· Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for fosaprepitant (MK-0517) + ondansetron, covering 2018-03-08 to 2018-03-08. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) [Phase 3]

See pricing